Janux Therapeutics, Inc. (JANX) Tops Q2 EPS by 20c

Janux Therapeutics, Inc. (NASDAQ: JANX) reported Q2 EPS of ($0.11), $0.20 better than the analyst estimate of ($0.31). Revenue for the quarter came in at $8.89 million versus the consensus estimate of $772 thousand.

For earnings history and earnings-related data on Janux Therapeutics, Inc. (JANX) click here.

You May Also Be Interested In

• Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
• U.S. Seeks to Phase Out Russian Uranium Ahead of Full-Ban on Imports - DJ
• LendingTree (TREE) 2877 contracts of October 30 calls trade, share price up 4.6%